| Date Filed | Type | Description |
| 10/04/2023 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 2,942 shares
@ $12.68, valued at
$37.3k
|
|
| 01/19/2023 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 2,403 shares
@ $21.2413, valued at
$51k
|
|
| 10/05/2022 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 2,587 shares
@ $18.73, valued at
$48.5k
|
|
| 06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/18/2022 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 984 shares
@ $9.05, valued at
$8.9k
|
|
| 01/20/2022 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Granted 20,500 shares
@ $0
Granted 82,000 options to buy
@ $8.27, valued at
$678.1k
|
|
| 12/17/2021 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Granted 11,100 shares
@ $0
Granted 82,265 options to buy
@ $9.23, valued at
$759.3k
|
|
| 10/06/2021 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 2,659 shares
@ $33.17, valued at
$88.2k
|
|
| 06/29/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/18/2021 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Sold 132 shares
@ $48.87, valued at
$6.5k
Granted 11,100 shares
@ $0
Granted 49,900 options to buy
@ $47.79, valued at
$2.4M
|
|
| 12/11/2020 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Exercised 207 options to buy
@ $34.43, valued at
$7.1k
|
|
| 11/18/2020 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Exercised 2,697 options to buy
@ $34.43, valued at
$92.9k
|
|
| 10/06/2020 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 2,632 shares
@ $51.1467, valued at
$134.6k
|
|
| 06/25/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/20/2020 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Granted 1,760 shares
@ $0
Granted 10,520 options to buy
@ $54.87, valued at
$577.2k
|
|
| 01/28/2020 |
4
| Sherman Matthew L (Director) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.|
Txns:
| Granted 20,000 options to buy
@ $3.23, valued at
$64.6k
|
|
| 10/17/2019 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.|
Txns:
| Granted 35,000 shares
@ $0
Granted 150,000 options to buy
@ $34.43, valued at
$5.2M
|
|
| 10/08/2019 |
3
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 3 on Deciphera Pharmaceuticals, Inc. |
| 08/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2019 |
4
| Sherman Matthew L (Director) has filed a Form 4 on Pulmatrix, Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.06, valued at
$15.9k
|
|
| 05/14/2019 |
4
| Sherman Matthew L (Director) has filed a Form 4 on NEWLINK GENETICS CORP|
Txns:
| Granted 25,000 options to buy
@ $1.69, valued at
$42.3k
|
|
| 01/29/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/25/2018 |
4
| Sherman Matthew L (Director) has filed a Form 4 on PIERIS PHARMACEUTICALS, INC.|
Txns:
| Granted 30,000 options to buy
@ $4.46, valued at
$133.8k
|
|
| 10/25/2018 |
3
| Sherman Matthew L (Director) has filed a Form 3 on PIERIS PHARMACEUTICALS, INC. |
| 06/06/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/25/2018 |
4
| Sherman Matthew L (Director) has filed a Form 4 on NEWLINK GENETICS CORP|
Txns:
| Granted 27,777 options to buy
@ $5.33, valued at
$148.1k
|
|
| 05/01/2018 |
3
| Sherman Matthew L (Director) has filed a Form 3 on NEWLINK GENETICS CORP |
| 04/05/2018 |
4
| Sherman Matthew L (Director) has filed a Form 4 on Pulmatrix, Inc.|
Txns:
| Bought 20,000 shares
@ $0
Bought 20,000 options to buy
@ $0.65, valued at
$13k
Bought 20,000 options to buy
@ $0.75, valued at
$15k
|
|
| 04/04/2018 |
4
| Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on ACCELERON PHARMA INC|
Txns:
| Sold 3,700 shares
@ $38.28, valued at
$141.6k
Sold 900 shares
@ $39.04, valued at
$35.1k
|
|
| 01/04/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/14/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/07/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/22/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|